Nijmegen Institute for Scientist-Practitioner in Addiction (NISPA), Radboud University, Nijmegen, the Netherlands; Radboudumc, Department of Psychiatry, Nijmegen, the Netherlands; Novadic-Kentron Addiction Treatment Center, Vught, the Netherlands.
Nijmegen Institute for Scientist-Practitioner in Addiction (NISPA), Radboud University, Nijmegen, the Netherlands; Novadic-Kentron Addiction Treatment Center, Vught, the Netherlands.
Int J Drug Policy. 2021 Aug;94:103230. doi: 10.1016/j.drugpo.2021.103230. Epub 2021 Apr 20.
Over the past decades gamma-hydroxybutyrate (GHB) has emerged as a popular drug with high potential of (ab)use due to its euphoric and relaxing effects. An overview of different populations using GHB is urgently needed, since this would enable development of adequate prevention and treatment policies to diminish the risks associated with GHB use. We systematically reviewed literature on different GHB using populations, comparing demographic characteristics, GHB use patterns, psychosocial aspects and psychiatric comorbidity.
We conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using Rayyan software. Original studies published from January 1997 up to October 2019 on GHB use were included. Out of 80 full-text articles, 60 articles of 51 unique studies were included. Most studies included people using GHB 1) presenting at emergency departments (n = 22), 2) recruited from the general population (n = 11), or 3) presenting at addiction care (n = 8).
Three main sub-populations of people using GHB are described in the literature: people using GHB recreationally without adverse effects; people using GHB recreationally with adverse effects, and people with dependence on GHB. These groups show considerable overlap in gender, age range, and comorbid substance use, as well as amount of GHB use per occasion. Differences are related to frequency and function of GHB use, the number of comas experienced, as well as work status, and psychiatric comorbidity.
Policy interventions should aim at preventing the transition from recreational substance use to GHB use, as most users are experienced recreational substance users prior to starting GHB use. When people use GHB regularly, interventions should aim at reducing the level of GHB use and preventing GHB use-related harm. Longitudinal studies and population-based probability sampling are required for more insight in the dynamics of GHB use in different sub-populations, and the transition from one group to the other, ultimately leading to dependence on GHB.
在过去几十年中,γ-羟基丁酸(GHB)因其令人愉悦和放松的效果而成为一种流行的药物,具有很高的滥用潜力。由于 GHB 的使用与风险相关,因此急需了解不同人群使用 GHB 的情况,以便制定适当的预防和治疗政策来降低这些风险。我们系统地综述了不同 GHB 使用人群的文献,比较了人口统计学特征、GHB 使用模式、心理社会方面和精神共病。
我们按照系统评价和荟萃分析的首选报告项目(PRISMA)指南,使用 Rayyan 软件进行了系统综述。纳入了 1997 年 1 月至 2019 年 10 月发表的关于 GHB 使用的原始研究。在 80 篇全文文章中,有 60 篇文章来自 51 项独特的研究。大多数研究包括在急诊室就诊的 1) 使用 GHB 的人(n=22)、2) 从普通人群中招募的人(n=11)或 3) 在戒毒治疗中心就诊的人(n=8)。
文献中描述了三种主要的 GHB 使用人群:无不良反应的娱乐性 GHB 使用者;有不良反应的娱乐性 GHB 使用者和 GHB 依赖者。这些群体在性别、年龄范围、合并物质使用以及每次使用 GHB 的量方面存在相当大的重叠。差异与 GHB 使用的频率和功能、经历的昏迷次数以及工作状况和精神共病有关。
政策干预应旨在防止从娱乐性物质使用向 GHB 使用的转变,因为大多数使用者在开始使用 GHB 之前是有经验的娱乐性物质使用者。当人们经常使用 GHB 时,干预措施应旨在减少 GHB 的使用量并预防 GHB 使用相关的危害。需要进行纵向研究和基于人群的概率抽样,以更深入地了解不同亚人群中 GHB 使用的动态以及从一个群体向另一个群体的转变,最终导致对 GHB 的依赖。